In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...